Home Biosimilar Antibodies Transmembrane Transporters CD markers Tisotumab vedotin
For research use only. Not for use in humans.

Tisotumab vedotin

Synonyms: TF-011-MMAE；HuMax-TF-ADC

Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.

Tisotumab vedotin

CAS No. 1418731-10-8

Click to purchase products related to Tisotumab vedotin

Quality Control

Batch: Purity: 99% Protein concentration: 9.162mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer.
References

Product Details

CAS No. 1418731-10-8
DAR 4.2
ADC antiody Tisotumab
ADC cytotoxin MMAE
Formulation 1xPBS
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07672782 NOT_YET_RECRUITING Drug: Tisotumab Vedotin Vulvar Carcinoma; Recurrent or Metastatic Vulvar Cancer; Squamous Cell Carcinoma Vulva GOG Foundation 2026-11 PHASE2
NCT06459180 ACTIVE_NOT_RECRUITING Drug: Pemetrexed|Drug: Topotecan|Drug: Vinorelbine|Drug: Gem Cervical Cancer Merck Sharp & Dohme LLC 2024-07-24 PHASE3
NCT03485209 ACTIVE_NOT_RECRUITING Drug: tisotumab vedotin|Drug: pembrolizumab|Drug: carboplati Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Exocrine Pancreatic Cancer; Carcinoma, Squamous Cell of Head and Neck Seagen, a wholly owned subsidiary of Pfizer 2018-06-25 PHASE2
NCT03786081 TERMINATED Drug: Tisotumab Vedotin|Drug: Bevacizumab|Drug: Pembrolizuma Cervical Cancer Seagen, a wholly owned subsidiary of Pfizer 2019-02-27 PHASE1; PHASE2
NCT05866354 COMPLETED Drug: Tisotumab Vedotin Solid Malignancies Zai Lab (Shanghai) Co., Ltd. 2023-06-16 PHASE1
NCT04697628 COMPLETED Drug: tisotumab vedotin|Drug: topotecan|Drug: vinorelbine|Dr Cervical Cancer Seagen, a wholly owned subsidiary of Pfizer 2021-02-22 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-06-29)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.